Biocept Blood-Based Test for Prostate Cancer and Breast Cancer

Jan 07, 2016

Biocept has launched a CLIA-validated androgen receptor expression assay that uses a patient's blood to detect and monitor late-stage prostate cancer and a certain form of breast cancer. The assay uses circulating tumor cells from a simple blood draw to detect androgen receptor expression, which is prevalent in patients with advanced prostate cancer. The androgen receptor is also found in a subset of patients with estrogen receptor-negative, progesterone receptor-negative and Her2-negative breast cancer, known as triple negative breast cancer. 

More Like This

Oct 18, 2018

Ubiquitome Liberty16

Ubiquitome has launched the Liberty16, a quantitative PCR system designed for personal and mobile DNA quantitation and testing. The Liberty16 has dimensions of 21.2 cm long (closed) by 11 cm wide by 11.5 cm tall, and weighs about 3.2 kg. It runs on a light, small, and rechargeable lithium battery for two to three hours of cord-free run time. The instrument can be Bluetooth paired with an iPhone app for laptop-free standalone operation. It is compatible with standard consumables and chemistries including Taqman and SYBR, and uses the industry-standard eight-strip PCR tube and cap format.

The instrument starts at $1,500 and Ubiquitome is taking pre-orders from researchers on a 'first-come, first-served" basis.

Oct 18, 2018

CeGaT Standalone TMB Analysis

CeGaT is now offering the analysis of tumor mutational burden (TMB) as a standalone diagnostic. CeGaT's TMB analysis has been available since 2017, as a part of its Somatic Tumor Panel for Treatment Decisions. Offered as a stand-alone analysis, the TMB diagnostic is now available with shorter turnaround times, improved cost-efficiency, and features CeGaT's high quality.

Oct 17, 2018

Genoox Integrated Platform

Bionano Genomics and Genoox have launched the Genoox Integrated Platform for identification of structural variants. The companies announced in April that they had partnered to develop a genome informatics workflow, which would integrate and annotate Bionano's structural variant calls with sequencing data within the Genoox platform. 

Bionano said its Saphyr system, combined with its new DLS labeling chemistry and analysis tools, calls structural variants better than sequencing-based methods, and that by applying Genoox's variant classification technology to align short read sequence data to its structural variant calls, the high sensitivity of Bionano calls would be combined with the base-pair precision of NGS. The Genoox Integrated Platform further automatically validates and confirms structural variant calls and integrates and annotates structural variants with smaller sequence variants in the same genome, the firms said. It provides sensitive, accurate detection of structural variation and genetic mutations, helping to speed genetic diagnosis.

The new platform combines raw NGS read data with Bionano-based structural variant calls from a single patient. Bionano's structural variant data are used to guide the alignment of NGS reads. Detected structural variants, copy number variants, indels, and single nucleotide variants are then annotated by aggregating data from multiple clinical and population frequency databases, and automated AI-based classification according to ACMG guidelines, according to the companies. The platform then generates a customizable clinical report on all variants, including Bionano-only and NGS-only calls.

Genoox and Bionano will co-sell and co-market the integrated platform.

Oct 17, 2018

Sophia Genetics Alamut Genova

Sophia Genetics has released Alamut Genova, a genome browser for variant exploration. The new product builts on Alamut Visual, which became part of the Sophia portfolio when the company acquired Interactive Biosoftware in June. Alamut Genova features ACMG/AMP classification, 3D protein visualization, Sanger electropherogram visualization, and a set of new splicing predictions.

Oct 16, 2018

DNAnexus Apollo

DNAnexus has released its DNAnexus Apollo platform for clinico-genomic data science exploration, analysis, and discovery. The platform provides a scalable cloud environment, flexible data models, as well as intuitive analysis and visualization tools for research and development teams. According to DNAnexus, pharmaceutical research and development teams can use the platform in their translational informatics research to quickly tests hypotheses and learn more about the mechanisms of action, biomarkers and targets. 

Oct 15, 2018

Roche NGS Avenio Tumor Tissue Analysis Kits

Roche has launched three next-generation sequencing Avenio tumor tissue analysis kits for oncology research: the Avenio Tumor Tissue Targeted Kit, Expanded Kit, and Surveillance Kit. The new kits complement the company's NGS ctDNA kits. They use formalin-fixed paraffin-embedded tissue and have a workflow of five days. The Avenio Tumor Tissue Targeted Kit covers 17 genes to identify guideline-related biomarkers. The Avenio Tumor Tissue Expanded Kit is a 77-gene assay with both guideline-related and emerging biomarkers. The Avenio Tumor Tissue Surveillance Kit covers 197 genes and is intended for establishing a baseline for variants in longitudinal tumor burden monitoring.

Oct 15, 2018

Empirical Biosciene EB Pure Total RNA & DNase 1 Digestion Kits

Emiprical Bioscience has launched its EB Pure Total RNA kit and the EB Pure DNase 1 Digestion kit to quickly and reliably purify RNA from cells or soft tissue. 

The firm's EB Pure Total RNA Kit reversibly binds RNA under optimized conditions, allowing researchers to remove proteins and other contaminants from the sample. The tool also allows RNA binding in high-salt and elution in a low-salt buffer. Each column can bind up to 100 microliters and does not need organic extractions or additional precipitations. The tool produces high and stable recovery rates within 20 minutes. The EB Pure DNase 1 Digestion kit can be used alongside the EB Pure Total RNA Kit in order for further DNA removal, the firm said.  

Oct 11, 2018

Pacific Biosciences Sequel System 6.0

Pacific Biosciences has launched updates to its Sequel sequencing system, including software version 6.0, reagents version 3.0, and SMRT cells 1M v3. Together, these changes, which are part of the Sequel System 6.0 release, result in sequence reads with greater than 99 percent accuracy, throughput of up to 50 gigabases per SMRT cell, and average read lengths of up to 100 kilobases, depending on the insert size, the firm said. For amplicon sequencing and RNA sequencing, customers can generate up to 500,000 reads with single-read accuracy greater than 99 percent. For whole-genome sequencing, customers can generate up to 20 gigabases of data per SMRT cell, with average read lengths of up to 30 kilobases.

Oct 11, 2018

Cellecta CloneTracker XP Expressed Lentiviral Barcode Library and Barcoded CRISPR Library

Cellecta has launched the CloneTracker XP Expressed Lentiviral Barcode Library and CloneTracker XP Barcoded CRISPR Library product lines. The new CloneTracker XP Barcode Libraries differ from Cellecta's standard CloneTracker Barcode Library in that the unique DNA sequence is designed to express on an RNA transcript in the cells. The libraries can therefore be detected by either DNA or RNA sequencing. Researchers can use these libraries to label several million cells each with a unique barcode, subsequently performing NGS to sort out sub-populations of progeny cells derived from the original progenitors at any point during the experiment.

Additionally, a variation of the new CloneTracker XP barcode labeling product introduces a gene effector, in this case CRISPR sgRNA, into the barcode library. Each effector targets and disrupts a specific gene in each of the cells that pick up a barcode. In combination with cell-specific barcode tracking, this knockout helps researchers see how specific genetic disruptions change the cells' characteristics while simultaneously identifying the genetic pathways that are activated to produce them. The firm offers two small, pre-made CloneTracker XP Barcoded CRISPR knockout libraries targeting 27 human and mouse anti-cancer genes, as well as custom library development services for CloneTracker XP Barcoded CRISPR Libraries. The CloneTracker XP Expressed Barcode Libraries are available with barcodes expressed in the 3′- or 5′-UTR of an RNA transcript, and with fluorescent or chemiluminescent reporters.

Oct 11, 2018

Paragon Genomics CleanPlex UMI Lung Cancer Panel

Paragon Genomics will introduce its research-use-only CleanPlex UMI Lung Cancer Panel at the upcoming American Society of Human Genetics Meeting. The panel is a targeted resequencing assay designed for the detection of ultralow-frequency variants across the hotspot regions of 23 genes frequently associated with lung cancer. The CleanPlex UMI technology incorporates unique molecular identifiers that distinguish between the two strands of DNA, enabling correction of PCR and sequencing errors to achieve more accurate results. The product can be used to prepare sequencing-ready libraries in a single-tube format in 3.5 hours, and variants at 0.1 percent allele frequency can be detected with high specificity using only 30 ng of DNA, Paragon said. CleanPlex NGS Panels are available for use with Illumina or Life Technologies Ion Torrent platforms.

Oct 10, 2018

Oxford Nanopore 'Rev D' Flow Cells

Oxford Nanopore Technologies has released a new version of the flow cell for the MinIon and GridIon sequencers that include the 'Rev D' ASIC. The new flow cells can be used for a longer time and yield up to 30 gigabases of data.

Oct 10, 2018

Oxford Nanopore MinIT

Oxford Nanopore Technologies has launched the MinIT, a compute module for use with the MinIon sequencer. MinIT is equipped with a Nvidia AGX system for real-time high-throughput data analysis and is preconfigured with software for MinIon set up and operation. Users can operate the module using either a tablet or mobile phone. MinIT runs both the instrument software MinKnow and the real-time analysis platform for nanopore data EPI2ME. Customers can power the tool using battery packs, which are available separately.

Oct 10, 2018

L7 Enterprise Science Platform 2.0

L7 Informatics, formerly known as Lab7 Systems, has introduced version 2.0 of its Enterprise Science Platform, featuring a validated, pre-built connection to the Microsoft Genomics service so users can run bioinformatics pipelines on the Microsoft Azure cloud. The release also includes workflow chaining to support multivariable processes, as well as support for next-generation sequencing, translational research, and cell therapy applications, plus a new user interface.

Oct 09, 2018

MDNA Life Sciences Mitomic Prostate Test

MDNA Life Sciences has announced the UK release for its PCR-based Mitomic Prostate Test (MPT). The MPT is a liquid biopsy assay optimized for the early detection of prostate cancer in advance of biopsy. The firm designed the MPT for testing men with clinical suspicion of prostate cancer to determine their likelihood of clinically significant cancer that may benefit from rapid intervention. The test will run on MDNA's CE-IVD kit, which contains the needed reagents to process up to 21 patient samples at a time.

Oct 05, 2018

Stratify Genomics Prompt Prostate Cancer Test

Stratify Genomics has announced Prompt, its new lab-developed test to track a man's genetic predisposition to prostate cancer. According to the firm, Prompt incorporates genetic information from several prostate cancer-risk associated SNPs. Using population-based analyses, the test reports how many men (out of 100) with a given genetic score would go on to develop prostate cancer. Clinicians can perform the test with a cheek swab sample to help men know their individual risk and potentially identify high-risk individuals.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.